Diverse long-time progression-free survival (PFS) and overall survival (OS), based on metastasis location, in metastatic urothelial carcinoma (MUC) patients treated with pemetexed (P) in monotherapy: Results from a longer follow-up of Arco del Mediterraneo Group
Cervera Grau, J., Gonzalez-Billalabeitia, E., Lopez, A., Juanidal, O., Satre, J., Barrajon, E., Esquerdo, G., Molins, C., Maciá, S., Rolfo, C. D.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article